Table 1.
Patient characteristics
| Training cohort |
Validation cohort |
P∗ | |
|---|---|---|---|
| n = 610 | n = 852 | ||
| Date of allo-SCT | 09/2001-06/2014 | 01/2010-12/2013 | |
| Median age at allo-SCT (y, range) | 53 (18-75) | 52 (17-78) | .090 |
| Recipient sex | .830 | ||
| Female | 236 (38.7%) | 335 (39%) | |
| Male | 374 (61.3%) | 517 (61%) | |
| Donor sex | <.001 | ||
| Female | 203 (33.3%) | 312 (37%) | |
| Male | 407 (66.7%) | 494 (58%) | |
| Missing | 0 (0.0%) | 46 (5%) | |
| Donor relation | <.001 | ||
| MRD | 193 (31.6%) | 211 (25%) | |
| MUD | 304 (49.8%) | 473 (56%) | |
| MMUD | 100 (16.4%) | 106 (12%) | |
| MMRD | 7 (1.1%) | 8 (1%) | |
| Haplo | 6 (1.0%) | 13 (2%) | |
| UCB | 0 (0.0%) | 41 (5%) | |
| HLA mismatch | .590 | ||
| No | 497 (81.5%) | 684 (80%) | |
| Yes | 113 (18.5%) | 168 (20%) | |
| Disease | <.001 | ||
| AML | 184 (30.2%) | 375 (44%) | |
| MPN | 47 (7.7%) | 131 (15%) | |
| Lymphoma | 176 (28.9%) | 99 (12%) | |
| MM | 70 (11.5%) | 31 (4%) | |
| MDS | 66 (10.8%) | 93 (11%) | |
| ALL | 67 (11.0%) | 93 (11%) | |
| Other | 0 (0.0%) | 30 (4%) | |
| ATG | <.001 | ||
| No | 221 (36.2%) | 504 (59%) | |
| Yes | 389 (63.8%) | 347 (41%) | |
| NA | 0 (0.0%) | 1 (0%) | |
| GVHD prophylaxis | <.001 | ||
| MMF | 397 (65.1%) | 362 (43%) | |
| MTX | 213 (34.9%) | 490 (57%) | |
| Conditioning | <.001 | ||
| MAC, apl | 107 (17.5%) | 474 (56%) | |
| RIC | 503 (82.5%) | 378 (44%) | |
| History of aGVHD | <.001 | ||
| None | 379 (62%) | 255 (27%) | |
| Grades 1-2 | 206 (34%) | 634 (66%) | |
| Grades 3-4 | 25 (4%) | 65 (7%) | |
| cGVHD (positive/available [%]) | 323/554 (58%) | 379/653 (58%) | .926 |
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; ATG, antithymocyte globulin; apl, aplasia conditioning; MAC, myeloablative conditioning; MM, multiple myeloma; MMF, mycofenolat mofetil; MMRD, mismatched related donor; MMUD, mismatched unrelated donor; MPN, myeloproliferative neoplasm; MRD, matched related donor; MUD, matched unrelated donor; MTX, methotrexate; NA, not available; RIC, reduced-intensity conditioning; UCB, umbilical cord blood.
∗
Kruskal-Wallis test; all other statistics were calculated with Mann Whitney U test.